Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jan:145:102831.
doi: 10.1016/j.critrevonc.2019.102831. Epub 2019 Nov 13.

Prevention of chemotherapy-induced peripheral neuropathy: A review of recent findings

Eiman Y Ibrahim  1 , Barbara E Ehrlich  2
Affiliations
Review

Prevention of chemotherapy-induced peripheral neuropathy: A review of recent findings

Eiman Y Ibrahim et al. Crit Rev Oncol Hematol. 2020 Jan.

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) is an adverse effect of chemotherapy that is frequently experienced by patients receiving treatment for cancer. CIPN is caused by many of the most commonly used chemotherapeutic agents, including taxanes, vinca alkaloids, and bortezomib. Pain and sensory abnormalities may persist for months, or even years after the cessation of chemotherapy. The management of CIPN is a significant challenge, as it is not possible to predict which patients will develop symptoms, the timing for the appearance of symptoms can develop anytime during the chemotherapy course, there are no early indications that warrant a reduction in the dosage to halt CIPN progression, and there are no drugs approved to prevent or alleviate CIPN. This review focuses on the etiology of CIPN and will highlight the various approaches developed for prevention and treatment. The goal is to guide studies to identify, test, and standardize approaches for managing CIPN.

Keywords: CIPN; Chemotherapy; Cisplatin; Neuropathy; Oxaliplatin; Paclitaxel; Taxanes; Vinca alkaloids.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

Figures

Fig. 1.
Fig. 1.
Illustration demonstrating sites of action of agents involved in chemotherapy induced peripheral neuropathy (CIPN) development.
See this image and copyright information in PMC

References

    1. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiology and Prevention Biomarkers. 2010;19(8):1893–907. - PubMed
    1. Ferguson T, Wilcken N, Vagg R, Ghersi D, Nowak AK. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database of Systematic Reviews. 2007(4). doi: 10.1002/14651858.CD004421.pub2. PubMed PMID: CD004421. - DOI - PubMed
    1. Argyriou AA, Koltzenburg M, Polychronopoulos P, Papapetropoulos S, Kalofonos HP. Peripheral nerve damage associated with administration of taxanes in patients with cancer. Critical reviews in oncology/hematology. 2008;66(3):218–28. - PubMed
    1. Carozzi VA, Canta A, Chiorazzi A. Chemotherapy-induced peripheral neuropathy: What do we know about mechanisms? Neuroscience letters. 2015;596:90–107. Epub 2014/12/03. doi: 10.1016/j.neulet.2014.10.014. PubMed PMID: 25459280. - DOI - PubMed
    1. Park S, Krishnan A, Lin C, Goldstein D, Friedlander M, Kiernan M. Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. Current medicinal chemistry. 2008;15(29):3081–94. - PubMed

MeSH terms